C4 Therapeutics Inc (CCCC) is ready for next Episode as it posted an annual sales of 20,760 K

C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Tuesday, down -5.19% from the previous trading day, before settling in for the closing price of $8.10. Over the past 52 weeks, CCCC has traded in a range of $1.06-$11.88.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.65%. While this was happening, its average annual earnings per share was recorded 30.76%. With a float of $57.73 million, this company’s outstanding shares have now reached $60.47 million.

The extent of productivity of a business whose workforce counts for 145 workers is very important to gauge.

C4 Therapeutics Inc (CCCC) Insider Updates

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 15.85%, while institutional ownership is 63.54%.

C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions

In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.7 earnings per share (EPS), lower than consensus estimate (set at -$0.68) by -$0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 30.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.

C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators

Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 6.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.38.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.88 in one year’s time.

Technical Analysis of C4 Therapeutics Inc (CCCC)

The latest stats from [C4 Therapeutics Inc, CCCC] show that its last 5-days average volume of 1.62 million was inferior to 4.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 19.98%. Additionally, its Average True Range was 0.67.

During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 61.18%, which indicates a significant increase from 3.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.71% in the past 14 days, which was lower than the 202.11% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.05, while its 200-day Moving Average is $4.28. Now, the first resistance to watch is $7.89. This is followed by the second major resistance level at $8.09. The third major resistance level sits at $8.26. If the price goes on to break the first support level at $7.52, it is likely to go to the next support level at $7.35. Assuming the price breaks the second support level, the third support level stands at $7.15.

C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats

The company with the Market Capitalisation of 526.85 million has total of 68,601K Shares Outstanding. Its annual sales at the moment are 20,760 K in contrast with the sum of -132,490 K annual income. Company’s last quarter sales were recorded 3,260 K and last quarter income was -34,750 K.